How Effective, Safe is Mosunetuzumab/Polatuzumab Vedotin in Pretreated MCL?

Commentary
Video

Treatment with mosunetuzumab and polatuzumab vedotin led to a complete response rate of 79% in patients with mantle cell lymphoma.

Results from a phase 2 trial (NCT03671018) that evaluated mosunetuzumab-axgb (Lunsumio) plus polatuzumab vedotin-piiq (Polivy) showed that, in all patients (n = 42), the overall response rate (ORR) was 88%, with complete responses (CRs) in 79% of patients and partial responses in 9%.

Notably, the ORR was 83% in patients at least 70 years old (n = 18), 91% in patients who received prior CAR T-cell therapy (n = 11), 93% in those with a Ki-67 index score of at least 50%, and 94% in those with pleomorphic/blastoid MCL.

The median progression-free survival and overall survival were 18.6 months (95% CI, 13.9-not estimable [NE]) and 20.7 months (95% CI, 17.0-NE), respectively.

Regarding safety, grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 41% of patients. Any-grade cytokine release syndrome (CRS) occurred in 43% of patients, with no grade 3 or higher events; the median CRS duration and time to first CRS onset relative to last dose were 3 days (range, 1-9) and 2 days (range, 1-5), respectively.

These data were most recently shared at the Society of Hematologic Oncology 2025 Annual Meeting by Michael Wang, MD, a professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, who spoke with CancerNetwork® about the most prominent takeaways from the trial.

Transcript:

What were the primary findings with this treatment combination?

The primary objective was the ORR. The ORR in this population was 88%, [which is] probably a record in this population. The CR rate in this very hard-to-treat lymphoma [population] was 79%. This is tremendous, and this is a breakthrough in this very sick population. Not only was the ORR high at 88% [and] the CR rate was high at 79%, but across all the bad risk factors, the response rate was the same. That included older [patients], [patients with the] blastoid and pleomorphic subtype, and [those with] a Ki-67 [index score] over 50%. Most importantly, in the 13 patients with the TP53 mutation and deletion, the response rate was 100%. This is a very potent regimen.

Was there anything unexpected in the safety profile of this combination?

The safety [profile] was very light. Mosunetuzumab is a bispecific antibody; it can cause CRS or immune-effector cell-associated neurotoxicity syndrome [ICANS]. The CRS [occurred in] 43% of patients as grade 1 or 2, and there were no grade 3, 4, or 5 CRS toxicities. All the CRS [events] were resolved within the first cycle. The neurotoxicity, which is also indicative of the bispecific antibody therapy, was also very rare, with only 1 [patient] with a grade 1 or 2 [event]; there were no grade 3 neurotoxicities.

There were 5 patients who died from infection after the combination was given, including 3 [cases of COVID-19] and pneumonia; this trial was done during the [COVID-19] pandemic. One [patient died of] pneumonia, and another died from West Nile virus, which is very rare. In this population that had received a median of 3 prior therapies plus our therapy, this was a cause of profound immune compromise, therefore giving rise to the infection rate.

Reference

Wang ML, Kamdar M, Assouline S, et al. Fixed-duration outpatient subcutaneous mosunetuzumab + polatuzumab vedotin shows robust efficacy in a phase 2 study of relapsed/refractory (R/R) post-BTK inhibitor mantle cell lymphoma (MCL). Presented at the Society of Hematologic Oncology 2025 Annual Meeting; September 2-6, 2025. Houston, TX. Abstract MCL-1493.

Recent Videos
Patients with high-risk markers may especially benefit from the addition of daratumumab to lenalidomide as maintenance therapy for NDMM.
A machine learning method for scoring tumor-infiltrating lymphocytes may address variability in pathologist measurements.
Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.
A 2-way communication between providers and patients may help facilitate dose modifications to help better manage adverse effects.
Related Content